Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 90

1.

Peritoneal Dialysis Registry With 2012 Survey Report.

Hasegawa T, Nakai S, Moriishi M, Ito Y, Itami N, Masakane I, Hanafusa N, Taniguchi M, Hamano T, Shoji T, Yamagata K, Shinoda T, Kazama J, Watanabe Y, Shigematsu T, Marubayashi S, Morita O, Wada A, Hashimoto S, Suzuki K, Kimata N, Wakai K, Fujii N, Ogata S, Tsuchida K, Nishi H, Iseki K, Tsubakihara Y, Nakamoto H.

Ther Apher Dial. 2015 Dec;19(6):529-39. doi: 10.1111/1744-9987.12382.

PMID:
26768809
2.

Tumor-specific HSP90 inhibition as a therapeutic approach in JAK-mutant acute lymphoblastic leukemias.

Kucine N, Marubayashi S, Bhagwat N, Papalexi E, Koppikar P, Sanchez Martin M, Dong L, Tallman MS, Paietta E, Wang K, He J, Lipson D, Stephens P, Miller V, Rowe JM, Teruya-Feldstein J, Mullighan CG, Ferrando AA, Krivtsov A, Armstrong S, Leung L, Ochiana SO, Chiosis G, Levine RL, Kleppe M.

Blood. 2015 Nov 26;126(22):2479-83. doi: 10.1182/blood-2015-03-635821. Epub 2015 Oct 6.

3.

De novo renal cell carcinoma in a kidney allograft 20 years after transplant.

Banshodani M, Kawanishi H, Marubayashi S, Shintaku S, Moriishi M, Shimamoto F, Tsuchiya S, Dohi K, Ohdan H.

Case Rep Transplant. 2015;2015:679262. doi: 10.1155/2015/679262. Epub 2015 Feb 19.

4.

JAK-STAT pathway activation in malignant and nonmalignant cells contributes to MPN pathogenesis and therapeutic response.

Kleppe M, Kwak M, Koppikar P, Riester M, Keller M, Bastian L, Hricik T, Bhagwat N, McKenney AS, Papalexi E, Abdel-Wahab O, Rampal R, Marubayashi S, Chen JJ, Romanet V, Fridman JS, Bromberg J, Teruya-Feldstein J, Murakami M, Radimerski T, Michor F, Fan R, Levine RL.

Cancer Discov. 2015 Mar;5(3):316-31. doi: 10.1158/2159-8290.CD-14-0736. Epub 2015 Jan 8.

5.

Use of vitamin D receptor activator, incident cardiovascular disease and death in a cohort of hemodialysis patients.

Shoji T, Marubayashi S, Shigematsu T, Iseki K, Tsubakihara Y; Committee of Renal Data Registry; Japanese Society for Dialysis Therapy.

Ther Apher Dial. 2015 Jun;19(3):235-44. doi: 10.1111/1744-9987.12274. Epub 2014 Dec 19.

PMID:
25530222
6.

An overview of regular dialysis treatment in Japan (as of 31 December 2012).

Nakai S, Hanafusa N, Masakane I, Taniguchi M, Hamano T, Shoji T, Hasegawa T, Itami N, Yamagata K, Shinoda T, Kazama JJ, Watanabe Y, Shigematsu T, Marubayashi S, Morita O, Wada A, Hashimoto S, Suzuki K, Nakamoto H, Kimata N, Wakai K, Fujii N, Ogata S, Tsuchida K, Nishi H, Iseki K, Tsubakihara Y.

Ther Apher Dial. 2014 Dec;18(6):535-602. doi: 10.1111/1744-9987.12281. Erratum in: Ther Apher Dial. 2016 Jun;20(3):322-8.

PMID:
25523509
7.

Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis.

Meyer SC, Keller MD, Woods BA, LaFave LM, Bastian L, Kleppe M, Bhagwat N, Marubayashi S, Levine RL.

Blood. 2014 Oct 2;124(14):2280-4. doi: 10.1182/blood-2014-03-560441. Epub 2014 Aug 12.

8.

Improved targeting of JAK2 leads to increased therapeutic efficacy in myeloproliferative neoplasms.

Bhagwat N, Koppikar P, Keller M, Marubayashi S, Shank K, Rampal R, Qi J, Kleppe M, Patel HJ, Shah SK, Taldone T, Bradner JE, Chiosis G, Levine RL.

Blood. 2014 Mar 27;123(13):2075-83. doi: 10.1182/blood-2014-01-547760. Epub 2014 Jan 27.

9.

Overview of regular dialysis treatment in Japan (as of 31 December 2011).

Nakai S, Watanabe Y, Masakane I, Wada A, Shoji T, Hasegawa T, Nakamoto H, Yamagata K, Kazama JJ, Fujii N, Itami N, Shinoda T, Shigematsu T, Marubayashi S, Morita O, Hashimoto S, Suzuki K, Kimata N, Hanafusa N, Wakai K, Hamano T, Ogata S, Tsuchida K, Taniguchi M, Nishi H, Iseki K, Tsubakihara Y.

Ther Apher Dial. 2013 Dec;17(6):567-611. doi: 10.1111/1744-9987.12147.

PMID:
24330555
10.

An overview of regular dialysis treatment in Japan (as of 31 December 2010).

Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, Shigematsu T, Shinoda T, Shoji T, Suzuki K, Taniguchi M, Tsuchida K, Nakamoto H, Nishi H, Hashimoto S, Hasegawa T, Hanafusa N, Hamano T, Fujii N, Masakane I, Marubayashi S, Morita O, Yamagata K, Wakai K, Wada A, Watanabe Y, Tsubakihara Y.

Ther Apher Dial. 2012 Dec;16(6):483-521. doi: 10.1111/j.1744-9987.2012.01143.x.

PMID:
23190510
11.

Heterodimeric JAK-STAT activation as a mechanism of persistence to JAK2 inhibitor therapy.

Koppikar P, Bhagwat N, Kilpivaara O, Manshouri T, Adli M, Hricik T, Liu F, Saunders LM, Mullally A, Abdel-Wahab O, Leung L, Weinstein A, Marubayashi S, Goel A, Gönen M, Estrov Z, Ebert BL, Chiosis G, Nimer SD, Bernstein BE, Verstovsek S, Levine RL.

Nature. 2012 Sep 6;489(7414):155-9. doi: 10.1038/nature11303.

12.

Genetic resistance to JAK2 enzymatic inhibitors is overcome by HSP90 inhibition.

Weigert O, Lane AA, Bird L, Kopp N, Chapuy B, van Bodegom D, Toms AV, Marubayashi S, Christie AL, McKeown M, Paranal RM, Bradner JE, Yoda A, Gaul C, Vangrevelinghe E, Romanet V, Murakami M, Tiedt R, Ebel N, Evrot E, De Pover A, Régnier CH, Erdmann D, Hofmann F, Eck MJ, Sallan SE, Levine RL, Kung AL, Baffert F, Radimerski T, Weinstock DM.

J Exp Med. 2012 Feb 13;209(2):259-73. doi: 10.1084/jem.20111694. Epub 2012 Jan 23.

13.

Overview of regular dialysis treatment in Japan (as of 31 December 2009).

Nakai S, Iseki K, Itami N, Ogata S, Kazama JJ, Kimata N, Shigematsu T, Shinoda T, Shoji T, Suzuki K, Taniguchi M, Tsuchida K, Nakamoto H, Nishi H, Hashimoto S, Hasegawa T, Hanafusa N, Hamano T, Fujii N, Masakane I, Marubayashi S, Morita O, Yamagata K, Wakai K, Wada A, Watanabe Y, Tsubakihara Y.

Ther Apher Dial. 2012 Feb;16(1):11-53. doi: 10.1111/j.1744-9987.2011.01050.x.

PMID:
22248195
14.

Relationship between the cAMP levels in leukocytes and the cytokine balance in patients surviving gram negative bacterial pneumonia.

Matsumoto T, Hayamizu K, Marubayashi S, Shimizu K, Hamamoto A, Yamaguchi T, Hashizume J, Onabe T, Asahara T, Ohdan H.

J Clin Biochem Nutr. 2011 Mar;48(2):134-41. doi: 10.3164/jcbn.10-72. Epub 2011 Feb 26.

15.

Overview of regular dialysis treatment in Japan (as of 31 December 2008).

Nakai S, Suzuki K, Masakane I, Wada A, Itami N, Ogata S, Kimata N, Shigematsu T, Shinoda T, Syouji T, Taniguchi M, Tsuchida K, Nakamoto H, Nishi S, Nishi H, Hashimoto S, Hasegawa T, Hanafusa N, Hamano T, Fujii N, Marubayashi S, Morita O, Yamagata K, Wakai K, Watanabe Y, Iseki K, Tsubakihara Y.

Ther Apher Dial. 2010 Dec;14(6):505-40. doi: 10.1111/j.1744-9987.2010.00893.x.

PMID:
21118359
16.

HSP90 is a therapeutic target in JAK2-dependent myeloproliferative neoplasms in mice and humans.

Marubayashi S, Koppikar P, Taldone T, Abdel-Wahab O, West N, Bhagwat N, Caldas-Lopes E, Ross KN, Gönen M, Gozman A, Ahn JH, Rodina A, Ouerfelli O, Yang G, Hedvat C, Bradner JE, Chiosis G, Levine RL.

J Clin Invest. 2010 Oct;120(10):3578-93. doi: 10.1172/JCI42442. Epub 2010 Sep 13.

17.

Efficacy of the JAK2 inhibitor INCB16562 in a murine model of MPLW515L-induced thrombocytosis and myelofibrosis.

Koppikar P, Abdel-Wahab O, Hedvat C, Marubayashi S, Patel J, Goel A, Kucine N, Gardner JR, Combs AP, Vaddi K, Haley PJ, Burn TC, Rupar M, Bromberg JF, Heaney ML, de Stanchina E, Fridman JS, Levine RL.

Blood. 2010 Apr 8;115(14):2919-27. doi: 10.1182/blood-2009-04-218842. Epub 2010 Feb 12.

18.

An overview of regular dialysis treatment in Japan (as of 31 December 2007).

Nakai S, Masakane I, Shigematsu T, Hamano T, Yamagata K, Watanabe Y, Itami N, Ogata S, Kimata N, Shinoda T, Syouji T, Suzuki K, Taniguchi M, Tsuchida K, Nakamoto H, Nishi S, Nishi H, Hashimoto S, Hasegawa T, Hanafusa N, Fujii N, Marubayashi S, Morita O, Wakai K, Wada A, Iseki K, Tsubakihara Y.

Ther Apher Dial. 2009 Dec;13(6):457-504. doi: 10.1111/j.1744-9987.2009.00789.x.

PMID:
19954472
19.

A germline JAK2 SNP is associated with predisposition to the development of JAK2(V617F)-positive myeloproliferative neoplasms.

Kilpivaara O, Mukherjee S, Schram AM, Wadleigh M, Mullally A, Ebert BL, Bass A, Marubayashi S, Heguy A, Garcia-Manero G, Kantarjian H, Offit K, Stone RM, Gilliland DG, Klein RJ, Levine RL.

Nat Genet. 2009 Apr;41(4):455-9. doi: 10.1038/ng.342. Epub 2009 Mar 15.

20.

Overview of regular dialysis treatment in Japan as of 31 December 2006.

Nakai S, Masakane I, Akiba T, Shigematsu T, Yamagata K, Watanabe Y, Iseki K, Itami N, Shinoda T, Morozumi K, Shoji T, Marubayashi S, Morita O, Kimata N, Shoji T, Suzuki K, Tsuchida K, Nakamoto H, Hamano T, Yamashita A, Wakai K, Wada A, Tsubakihara Y.

Ther Apher Dial. 2008 Dec;12(6):428-56. doi: 10.1111/j.1744-9987.2008.00634.x.

PMID:
19140842
21.

Overview of regular dialysis treatment in Japan (as of 31 December 2005).

Nakai S, Masakane I, Akiba T, Iseki K, Watanabe Y, Itami N, Kimata N, Shigematsu T, Shinoda T, Syoji T, Syoji T, Suzuki K, Tsuchida K, Nakamoto H, Hamano T, Marubayashi S, Morita O, Morozumi K, Yamagata K, Yamashita A, Wakai K, Wada A, Tsubakihara Y.

Ther Apher Dial. 2007 Dec;11(6):411-41.

PMID:
18028170
22.

An overview of regular dialysis treatment in Japan (as of 31 December 2004).

Nakai S, Wada A, Kitaoka T, Shinzato T, Nagura Y, Kikuchi K, Masakane I, Shinoda T, Yamazaki C, Sakai R, Marubayashi S, Morita O, Iseki K, Usami T, Kimata N, Suzuki K, Tabei K, Fushimi K, Miwa N, Yauchi M, Wakai K, Akiba T.

Ther Apher Dial. 2006 Dec;10(6):476-97.

PMID:
17199880
23.

A case report of plasmapheresis in paraneoplastic cerebellar ataxia associated with anti-Tr antibody.

Taniguchi Y, Tanji C, Kawai T, Saito H, Marubayashi S, Yorioka N.

Ther Apher Dial. 2006 Feb;10(1):90-3.

PMID:
16556143
24.

Studies on post-transplant dyslipidemia in kidney transplant patients.

Marubayashi S, Ohdan H, Tashiro H, Tokita D, Onoe T, Hayamizu K, Asahara T, Doi S, Okumoto S, Tanji C, Kawai T, Taniguchi Y, Fukuda Y, Dohi K.

Hiroshima J Med Sci. 2005 Jun;54(2):39-45.

PMID:
15991596
25.

Studies on eleven kidney transplants from non-heart-beating donors.

Marubayashi SM, Tashiro H, Ohdan H, Tokita D, Hara H, Onoe T, Kitayama T, Hayamizu K, Asahara T, Doi S, Okumoto S, Taniguchi Y, Fukuda Y, Dohi K.

Hiroshima J Med Sci. 2004 Mar;53(1):7-11.

PMID:
15274425
26.

Allochronic overlapping malignancies after renal transplantation in a patient with p53 gene mutation: report of a case.

Kitayama T, Marubayashi S, Hayamizu K, Tashiro H, Ohdan H, Ikeda S, Okimoto T, Okajima M, Kataoka T, Sugino K, Asahara T, Fukuda Y, Dohi K.

Surg Today. 2004;34(5):473-6. Review.

PMID:
15108094
27.

Novel method using near-infrared spectroscopy to assess intrahepatic anastomosis between hepatic veins of right lobe graft in living-donor liver transplantation.

Ohdan H, Itamoto T, Tashiro H, Katayama K, Fudaba Y, Mizunuma K, Ishizaki K, Sugino K, Marubayashi S, Asahara T.

Transplant Proc. 2002 Nov;34(7):2781. No abstract available.

PMID:
12431609
28.

Effect of lazaroids on NF-kappa B activation of Kupffer cells in liver preservation.

Marubayashi S, Okada K, Fukuma K, Tashiro H, Kitayama T, Hayamizu K, Dohi K, Asahara T.

Transplant Proc. 2002 Nov;34(7):2662-3. No abstract available.

PMID:
12431566
29.

Beneficial effects of a Rho-associated coiled-coli forming protein serine/threonine kinase inhibitor, Y-27632, on survival of recipients in rat liver transplantation following warm ischemia.

Mizunuma K, Ohdan H, Tashiro H, Fudaba Y, Marubayashi S, Asahara T.

Transplant Proc. 2002 Nov;34(7):2643-4. No abstract available.

PMID:
12431558
30.

Percutaneous microwave coagulation therapy for primary or recurrent hepatocellular carcinoma: long-term results.

Itamoto T, Katayama K, Fukuda S, Fukuda T, Yano M, Nakahara H, Okamoto Y, Sugino K, Marubayashi S, Asahara T.

Hepatogastroenterology. 2001 Sep-Oct;48(41):1401-5.

PMID:
11677974
31.

Differential expression of CD45 isoforms in tolerant and rejecting rat liver transplant recipients.

Tashiro H, Shintaku S, Fudaba Y, Shinozaki K, Yahata H, Sakaguchi T, Marubayashi S, Asahara T.

Transplant Proc. 2001 Feb-Mar;33(1-2):544. No abstract available.

PMID:
11266949
32.

Donor bone marrow perioperatively administered via portal vein induced prolongation of skin allograft survival and microchimerism in liver-transplanted rats.

Tashiro H, Shintaku S, Fudaba Y, Yamamoto H, Shibata S, Mizunuma K, Okimasa S, Marubayashi S, Fukuda Y, Dohi K, Asahara T.

Transplant Proc. 2000 Nov;32(7):2363-4. No abstract available.

PMID:
11120201
33.

Study on eight patients with malignant tumors after renal transplantation.

Marubayashi S, Tashiro H, Watanabe H, Fudaba Y, Hayamizu K, Ohdan H, Okimasa S, Katayama K, Itamoto T, Haruta N, Okajima M, Kataoka T, Sugino K, Yahata H, Ishikawa T, Fukuda Y, Dohi K, Asahara T.

Hiroshima J Med Sci. 2000 Jun;49(2):117-20.

PMID:
10920578
34.

Effect of the 21-aminosteroid on nuclear factor-kappa B activation of Kupffer cells in endotoxin shock.

Okada K, Marubayashi S, Fukuma K, Yamada K, Dohi K.

Surgery. 2000 Jan;127(1):79-86.

PMID:
10660762
35.

Effect of lazaroid U-74389G and methylprednisolone on endotoxin-induced shock in mice.

Fukuma K, Marubayashi S, Okada K, Yamada K, Kimura A, Dohi K.

Surgery. 1999 Apr;125(4):421-30.

PMID:
10216533
36.

Granular cell tumor of the breast: report of a case.

Kohashi T, Kataoka T, Haruta R, Sugino K, Marubayashi S, Yahata H, Asahara T, Fujii S, Arihiro K, Dohi K.

Hiroshima J Med Sci. 1999 Mar;48(1):31-3.

PMID:
10213961
37.

Protective effect of monoclonal antibodies to adhesion molecules on rat liver ischemia-reperfusion injury.

Marubayashi S, Oshiro Y, Fukuma A, Okada K, Maeda T, Dohi K.

Transplant Proc. 1999 Feb-Mar;31(1-2):1054. No abstract available.

PMID:
10083471
38.

Preventive efficacy of 15-deoxyspergualin against progression of apoptotic cell death in acute rejection after rat liver transplantation.

Yamamoto H, Ohdan H, Shintaku S, Miyata Y, Marubayashi S, Asahara T, Ito H, Dohi K.

Transplant Proc. 1998 Dec;30(8):4104-5. No abstract available.

PMID:
9865313
39.

Effects of deoxyspergualin (DSG) administered in the chronic phase following kidney transplantation.

Fudaba Y, Fukuda Y, Yamamoto H, Ohdan H, Shintaku S, Shibata S, Miyata Y, Marubayashi S, Asahara T, Dohi K.

Transplant Proc. 1998 Nov;30(7):3582-3. No abstract available.

PMID:
9838569
40.

Examination of a nested polymerase chain reaction assay using polymorphic neutrophils for cytomegalovirus infection after kidney transplantation.

Sumimoto R, Fukuda Y, Nakayama T, Hoshino S, Takahashi M, Marubayashi S, Asahara T, Dohi K.

Transplant Proc. 1998 Nov;30(7):3146-8. No abstract available.

PMID:
9838392
41.

Expression of Bcl-2/Bax mRNA in grafted liver during acute rejection after rat liver transplantation.

Yamamoto H, Ohdan H, Shintaku S, Miyata Y, Marubayashi S, Asahara T, Ito H, Dohi K.

Transplant Proc. 1998 Nov;30(7):2950-1. No abstract available.

PMID:
9838300
42.

Analysis of Bcl-X in rat liver allograft: rejection-induced apoptosis is associated with up-regulation of Bcl-Xs expression.

Shintaku S, Ohdan H, Yamamoto H, Miyata Y, Shibata S, Fudaba Y, Noriyuki T, Marubayashi S, Asahara T, Fukuda Y, Dohi K.

Transplant Proc. 1998 Nov;30(7):2941-2. No abstract available.

PMID:
9838296
43.

Effect of the angiotensin-converting enzyme inhibitor enalapril on post-transplant erythrocytosis.

Marubayashi S, Yamamoto H, Shibata S, Fudaba Y, Miyata Y, Fukuma K, Okada K, Hinoi T, Ikeda M, Maeda T, Oshiro Y, Dohi K.

Hiroshima J Med Sci. 1998 Sep;47(3):121-4.

PMID:
9810784
44.

Factors affecting postoperative prognosis in the solitary-nodule type of hepatocellular carcinoma: experience of 132 cases in our institute.

Asahara T, Dohi K, Katayama K, Itamoto T, Okamoto Y, Nakahara H, Ono E, Sugino K, Marubayashi S, Yahata H, Kitamoto M, Nakanishi T, Azuma K, Ito K, Shimamoto F.

Hiroshima J Med Sci. 1998 Sep;47(3):99-104.

PMID:
9810780
45.

Malignant mesothelioma originating in the hepatic falciform ligament: report of a case.

Marubayashi S, Ohdan H, Asahara T, Ikeda M, Hinoi T, Fukuma K, Maeda T, Oshiro Y, Shimamoto F, Dohi K.

Surg Today. 1998;28(9):929-31.

PMID:
9744402
46.

Studies of postoperative transarterial infusion chemotherapy for liver metastasis of colorectal carcinoma after hepatectomy.

Asahara T, Kikkawa M, Okajima M, Ojima Y, Toyota K, Nakahara H, Katayama K, Itamoto T, Marubayashi S, One E, Yahata H, Dohi K, Azuma K, Ito K.

Hepatogastroenterology. 1998 May-Jun;45(21):805-11.

PMID:
9684138
47.

A case of abdominal aortic aneurysm associated with systemic lupus erythematosus.

Marubayashi S, Sugi K, Ishiyama K, Fukuma K, Okada K, Hinoi T, Ikeda M, Haruta H, Sugino K, Asahara T, Kawano H, Dohi K.

Hiroshima J Med Sci. 1998 Jun;47(2):85-7.

PMID:
9674345
48.

Tumor localization studies and surgical treatment in patients with insulinoma.

Marubayashi S, Tanaka T, Shimizu Y, Matugu Y, Fukuma K, Okada K, Hinoi T, Ikeda M, Maeda T, Oshiro Y, Miura Y, Dohi K.

Hiroshima J Med Sci. 1998 Jun;47(2):69-72.

PMID:
9674343
49.

Living related partial liver transplantation for primary biliary cirrhosis--a case report.

Asahara T, Dohi K, Sugino K, Marubayashi S, Ohdan H, Noriyuki T, Katayama K, Itamoto T, Nakanishi T, Tazuma S, Kajiyama G, Moriwaki K, Yuge O, Otani M, Okabayashi S, Yokoyama T, Shimamoto F, Itoh H, Yokoyama T.

Hiroshima J Med Sci. 1998 Mar;47(1):31-7.

PMID:
9583281
50.

Modulation of Kupffer cells affects the metabolism of protease inhibitor administered in cold-preserved liver transplantation.

Ohdan H, Fukuda Y, Asahara T, Miyata Y, Urushihara T, Sumimoto R, Marubayashi S, Dohi K.

Transplant Proc. 1997 Dec;29(8):3358-9. No abstract available.

PMID:
9414748

Supplemental Content

Loading ...
Support Center